 Efficacy of Doryx Delayed Release Tablets to doxycycline hyclate will be assessed using an Investigators Global Assessment IGA score and the absolute change from baseline to 12 weeks in inflammatory lesion count in patients with moderate to severe facial acne vulgaris. Additionally, the absolute change from baseline to 12 weeks in non-inflammatory lesions count of Doryx Delayed Release Tablets compared to doxycycline hyclate will be evaluated. 